» Articles » PMID: 11772976

Evaluation of Serum Cystatin C Concentration As a Marker of Renal Function in Patients with Cirrhosis of the Liver

Overview
Journal Gut
Specialty Gastroenterology
Date 2002 Jan 5
PMID 11772976
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Diagnosis of moderately impaired renal function is of particular importance in patients with cirrhosis of the liver. Whereas patients with a markedly impaired glomerular filtration rate can be diagnosed easily by elevated serum creatinine concentrations, moderately reduced renal function may be missed by this conventional parameter. Recently, cystatin C has been suggested as a sensitive marker of renal function, independent of sex or muscle mass. Therefore, the aim of this study was to investigate the value of serum cystatin C concentration for the detection of moderately impaired renal function.

Methods: Ninety seven in-hospital patients with cirrhosis and a 24 hour creatinine clearance of at least 40 ml/min were investigated and divided into group 1 (creatinine clearance > or = 70 ml/min; n = 55) and group 2 (creatinine clearance 40-69 ml/min; n = 42).

Results: Serum cystatin C concentrations (mean (SD): 1.31 (0.51) v 1.04 (0.34) mg/l (p = 0.008)) and creatinine concentrations (1.03 (0.52) v 0.86 (0.22) mg/100 ml (p=0.03)) were higher in group 2 than in group 1; there was no significant difference in urea concentrations. Receiver-operator characteristics (ROC) revealed a differential diagnostic advantage of cystatin C over creatinine and urea. At cut off concentrations of 1.0 mg/l, 0.9 mg/100 ml, and 28 mg/100 ml, respectively, cystatin C, creatinine, and urea exhibited 69%, 45%, and 44% sensitivity (p<0.05). As patients with a small muscle mass or reduced physical activity could be particularly prone to overestimation of their renal function, separate analyses were performed for the subgroups of female and Child-Pugh class C patients, respectively. In both groups, discrimination between patients with moderately impaired and normal renal function was best with cystatin C. In female patients, sensitivity of cystatin C (77.8%) was superior (p<0.05) to that of creatinine (38.9%) and urea (41.2%). In Child-Pugh C patients, the ROC curve was significantly better for cystatin C than for creatinine.

Conclusions: Serum cystatin C determination could be a valuable tool in patients with cirrhosis, particularly with Child-Pugh class C or in female patients, for early diagnosis of moderately impaired renal function.

Citing Articles

Correlation between serum markers and transjugular intrahepatic portosystemic shunt prognosis in patients with cirrhotic ascites.

Hu X, Yang X, Lu J, Li G, Dai J, Wang J World J Gastrointest Surg. 2024; 16(2):481-490.

PMID: 38463353 PMC: 10921209. DOI: 10.4240/wjgs.v16.i2.481.


From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.

Allegretti A, Patidar K, Ma A, Cullaro G Hepatology. 2024; .

PMID: 38353565 PMC: 11322426. DOI: 10.1097/HEP.0000000000000790.


Kidney disease in patients with chronic liver disease: Does sex matter?.

Cooper K, Colletta A, Moulton K, Ralto K, Devuni D World J Clin Cases. 2023; 11(17):3980-3992.

PMID: 37388789 PMC: 10303604. DOI: 10.12998/wjcc.v11.i17.3980.


Muscle mass and estimates of renal function: a longitudinal cohort study.

Groothof D, Post A, Polinder-Bos H, Erler N, Flores-Guerrero J, Kootstra-Ros J J Cachexia Sarcopenia Muscle. 2022; 13(4):2031-2043.

PMID: 35596604 PMC: 9398222. DOI: 10.1002/jcsm.12969.


A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis.

Chaney A Clin Exp Gastroenterol. 2021; 14:385-396.

PMID: 34675586 PMC: 8502008. DOI: 10.2147/CEG.S323778.


References
1.
Papadakis M, Arieff A . Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med. 1987; 82(5):945-52. DOI: 10.1016/0002-9343(87)90156-2. View

2.
Arroyo V, Gines P, Gerbes A, DUDLEY F, Gentilini P, Laffi G . Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23(1):164-76. DOI: 10.1002/hep.510230122. View

3.
Gerbes A . Medical treatment of ascites in cirrhosis. J Hepatol. 1993; 17 Suppl 2:S4-9. DOI: 10.1016/s0168-8278(05)80447-7. View

4.
Gerbes A, Gulberg V, Waggershauser T, Holl J, Reiser M . Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology. 1998; 28(3):683-8. DOI: 10.1002/hep.510280313. View

5.
Knoll E, Stamm D . [Specific determination of serum creatinine]. Z Klin Chem Klin Biochem. 1970; 8(6):582-7. View